

References

- World Health Organization. Global tuberculosis report 2017. Geneva: WHO; 2017. p 1-4.
- Yuen CM, Toivan AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant tuberculosis in children: a systematic review. *Pediatr Infect Dis J*. 2013;32:e217-26.
- Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis. 1994-2009. *PLoS One*. 2011;6:e22927.
- Yuen CM, Jenkins HE, Rodriguez CA, Keshavjee S, Becerra MC. Global and regional burden of isoniazid-resistant tuberculosis. *Pediatrics*. 2015;136:e50-9.
- Gegia M, Winters N, Benedetti A, van Soelingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. *Lancet Infect Dis*. 2017;17:223-34.
- Centro Nacional de Epidemiología, Instituto de Salud Carlos III. Informe epidemiológico sobre la situación de la tuberculosis en España. Año 2014. Madrid: Centro Nacional de Epidemiología; 2015.
- Steiner P, Rao M, Victoria M, Steiner M. Primary isoniazid-resistant tuberculosis in children. Clinical features, strain resistance, treatment, and outcome in 26 children treated at King County Medical Center of Brooklyn between the years 1961 and 1972. *Am Rev Respir Dis*. 1974;110:306-11.
- García-Prats AJ, du Plessis L, Draper HR, Burger A, Seddon JA, Zimri K, et al. Outcome of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children. *Int J Tuberc Lung Dis*. 2016;20:1469-76.
- Seddon JA, Perez-Velez CM, Schaaf HS, Furn JJ, Marais BJ, Tebruegge M, et al. Consensus statement on research definitions for drug-resistant tuberculosis in children. *J Pediatr Infect Dis Soc*. 2013;2:100-9.
- Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the genotype MTBDRplus assay for rifampin and isoniazid susceptibility testing of *Mycobacterium tuberculosis* strains and clinical specimens. *J Clin Microbiol*. 2007;45:2635-40.
- Mellado Peña MJ, Santiago García B, Baquero-Artigao F, Moreno Pérez D, Piñero Pérez R, Méndez Echevarría A, et al. Actualización del tratamiento de la tuberculosis en niños. *An Pediatr (Barc)*. 2018;88:52.e1-52.e12.
- Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis*. 2016;63:e147-95.
- National Institute for Health and Care Excellence. Tuberculosis. NICE guideline [NG33]. January; 2016 [accessed 1 Oct 2018]. Available in: <https://www.nice.org.uk/guidance/ng33/chapter/Recommendations-drug-resistant-tb>
- Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghlaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respir Med*. 2018;6:265-75.
- Mandalakas AM, Kirchner HL, Lombard C, Walzl G, Grewal HM, Gie RP, et al. Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. *Int J Tuberc Lung Dis*. 2012;16:1033-9.

Celia Morales Pérez,^a David Gomez-Pastrana,^{a,*} Carmen Aragón Fernández,^a Elvira Pérez Escolano^b

^a Unidad de Neumología Infantil, Servicio de Pediatría, Hospital Materno Infantil de Jerez, Jerez de la Frontera, Cádiz, Spain
^b Servicio de Medicina Interna, Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain

*Corresponding author.

E-mail address: dgpastranad@gmail.com (D. Gomez-Pastrana).

15/9-2129/
 © 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.



Do HIV-Infected Patients Die of Chronic Obstructive Pulmonary Disease in Western Countries?

¿En los países occidentales, los pacientes infectados con el VIH mueren de enfermedad pulmonar obstructiva crónica?

Dear Editor:

According to Global Burden of Disease estimates, at least 65 million people worldwide have moderate to severe chronic obstructive pulmonary disease (COPD). In addition to being globally prevalent, COPD was responsible for more than three million deaths in 2015 (5% of all deaths globally),¹ and from 1990 to 2015, the mortality rate increased 11.6%.² Furthermore, chronic respiratory diseases in the United States account for more than 155,000 deaths annually and are the third leading cause of death, surpassed only by heart disease and cancer.³

Recent systematic reviews report that up to 11% of people living with HIV (PLWH) have spirometric test results compatible with those for COPD.⁴ Furthermore, although PLWH smoke tobacco and other products at higher rates than other groups at risk for COPD, they are relatively younger, and the frequency of COPD appears higher than would be expected from smoking only.⁵ Proposed hypotheses have suggested that this increase in COPD prevalence could be due to several associated factors such as local inflammation, increased susceptibility to apoptosis and an altered antioxidant-oxidant balance.⁶

Currently, the presence of HIV infection is considered a risk factor for developing COPD, a finding just recently included in the latest GOLD document.⁷ This increased prevalence of COPD among PLWH, consistently observed in several studies performed in western countries, would suggest that mortality due to COPD among

PLWH could be at least similar to the rate observed in the general population, especially considering that recent studies from the same geographical environment have stated that COPD in PLWH can result in higher mortality rates than in the HIV-uninfected population.⁸ Surprisingly, however, published data from current cohorts of HIV-infected patients report low rates of death attributed to COPD, even less than 1% in some nationwide studies.⁹

This observation could be explained by different factors. First, with regard to death certificate coding, it is worth remembering that the immediate cause of death in COPD patients is usually due to exacerbations (half of which are infectious) and cardiovascular events.¹⁰ In both situations, actual codification systems, such as Code,¹¹ classify the events correctly as the immediate cause of death in HIV-infected patients; but probably tend to underestimate COPD as the underlying cause. Thus, when reporting causes of death in PLWH cohorts, COPD is usually not even reported to be within the top 10 causes. This misclassification phenomenon has previously been reported in the general population,¹² but some authors have suggested that it could be even more manifested in the HIV-infected population. The trend among practitioners who are not used to caring for PLWH is to codify infectious diseases as the cause of death, related or unrelated to HIV. As a consequence, could the number of deaths caused by infections unrelated to AIDS and cardiovascular disease be systematically reported more frequently in AIDS cohort studies?

Several examples might support this hypothesis. Recent data published from the Swiss HIV Cohort Study (SHCS) reported 1.7% of deaths due to COPD in 2005-2009, whereas the reported rates for non-AIDS-related infections and heart disease were 9.2% and 6.5%, respectively.¹³ Similarly, Croxford et al. reported that 0.75% of deaths were caused by COPD (1.78% after excluding AIDS-defining illnesses) while deaths by cardiovascular disease (including stroke) and non-AIDS-defining infections accounted for 7.86% and 7.45%,

respectively, of the total deaths (19% and 18% after excluding AIDS-defining illnesses).⁹

Another possible explanation, independent of the coding systems, could be that although PLWH frequently visit doctors and are linked to care, their lungs tend to be less tested and therefore less diagnosed with COPD. COPD underdiagnosis is a universal phenomenon, both in general and hospital-based populations.¹⁴ Spirometry is not actually implemented in most hospitals as a routine test for PLWH, despite guidelines having begun to include algorithms regarding this comorbidity.¹⁵ This underdiagnosis would then lead to an underreporting of deaths.

Both of these possible explanations, if true, may reflect a worrisome problem: COPD is not yet perceived as a relevant concern in PLWH care. This potential issue may also have caused collateral effects, as few research groups are presently addressing this particular comorbidity. In the last 10 years (2008–2017), only 191 articles indexed in Medline and related to HIV mention in their title, abstract, or keywords the term “COPD”, while in the same period, 931 articles and 8437 articles mention “cardiovascular” and “cancer”, respectively.

It is important to note that the scientific community still possesses an astonishing lack of knowledge in how COPD and HIV relate to each other. We do not yet have enough evidence regarding the effects of chronic HIV infection in the lungs; how these affect the local immunity, even in the presence of effective antiretroviral treatment; and how to optimize the management of COPD in PLWH, apart from implementing smoking cessation and programs to identify individuals with COPD. Further lung research in HIV is needed, and most, if not all, PLWH might be recommended to perform a baseline spirometry to aid in tracking their general and HIV-related health.

As a conclusion, we consider that the impact of COPD in terms of PLWH mortality could have been systematically and grossly underestimated in western countries. This misclassification phenomenon could have lead physicians to minimize COPD role as a comorbidity in this population.

References

1. Who.int. WHO | Burden of COPD; 2018 [Internet] Available from: <http://www.who.int/respiratory/copd/burden/en/> [accessed 23.02.18].
2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Respir Med.* 2017;5:691–706.
3. National Center for Health Statistics (US). Health, United States, 2016: With Chartbook on Long-term Trends in Health. Hyattsville (MD): National Center for Health Statistics (US); 2017 May. Report No.: 2017-1232.
4. Bigna JJ, Kenne AM, Asangbeh SL, Sibetcheu AT. Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. *Lancet Glob Health.* 2018;6:e193–202.
5. Mdege ND, Shah S, Ayo-Yusuf OA, Hakim J, Siddiqi K. Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries. *Lancet Glob Health.* 2017;5:e578–92.
6. Morris A, George MP, Crothers K, Huang L, Lucht L, Kessinger C, et al. HIV and chronic obstructive pulmonary disease: is it worse and why? *Proc Am Thorac Soc.* 2011;8:320–5. <http://dx.doi.org/10.1513/pats.201006-045WR>.
7. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. *Am J Respir Crit Care Med.* 2017;195:557–82.
8. Triplett M, Justice A, Attia EF, Tate J, Brown ST, Goetz MB, et al. Markers of Chronic Obstructive Pulmonary Disease are associated with mortality in people living with HIV. *AIDS.* 2018;32:487–93.
9. Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. *Lancet Public Health.* 2017;2:e35–46.
10. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax.* 2007;62:411–5.
11. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. *Epidemiology.* 2011;22:516–23.
12. Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. *Eur Respir J.* 2006;28:781–5.
13. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. *HIV Med.* 2013;14:195–207.
14. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. *Lancet.* 2009;374:721–32.
15. EACS Guidelines version 9.0, October 2017. [Internet] Available from: <http://www.eacsociety.org/files/guidelines.9.0-english.pdf> [accessed 23.02.18].

Francisco Fanjul,^{a,b,*} Joan Soriano^{c,d,1}

^a *Unidad de Enfermedades Infecciosas, Hospital Universitari Son Espases, Palma de Mallorca, Spain*

^b *Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain*

^c *Servicio de Neumología e Instituto de Investigación, Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Madrid, Spain*

^d *Methodological and Scientific Consultant of SEPAR, Spain*

* Corresponding author.

E-mail address: franciscoj.fanjul@ssib.es (F. Fanjul).

¹ www.separ.es.

1579-2129/

© 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.